Guy Young Selected Research

emicizumab

9/2021	Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making.
9/2021	Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
4/2021	Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.
3/2021	Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
1/2021	Management of children with hemophilia A: How emicizumab has changed the landscape.
1/2021	Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
1/2021	Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
1/2021	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
11/2020	Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child.
11/2020	Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guy Young Research Topics

Disease

49	Hemophilia A (Haemophilia) 07/2022 - 02/2005
42	Hemorrhage 07/2022 - 02/2005
17	Venous Thromboembolism 01/2022 - 02/2011
10	Thrombosis (Thrombus) 01/2022 - 01/2004
7	Hemophilia B (Haemophilia B) 11/2021 - 12/2014
5	Thrombophilia 01/2021 - 04/2010
4	Congenital Heart Defects (Congenital Heart Defect) 01/2022 - 04/2011
4	Thrombotic Microangiopathies 04/2021 - 01/2017
4	Venous Thrombosis (Deep-Vein Thrombosis) 10/2020 - 10/2011
3	Thromboembolism 01/2022 - 12/2008
3	Metrorrhagia (Spotting) 01/2021 - 01/2017
2	Hypersensitivity (Allergy) 07/2022 - 11/2021
2	Infections 01/2022 - 01/2018
2	Neoplasms (Cancer) 01/2021 - 01/2018
2	Obesity 01/2018 - 01/2012
2	Body Weight (Weight, Body) 01/2018 - 01/2011
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 09/2014 - 07/2006
2	Thrombocytopenia (Thrombopenia) 12/2011 - 12/2008
2	Joint Diseases (Joint Disease) 01/2006 - 02/2005
1	Pain (Aches) 07/2022
1	Embolism (Embolus) 01/2022
1	Embolic Stroke 01/2022
1	Myocardial Infarction 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Leukopenia 11/2020
1	Hematuria 11/2020
1	Lupus Nephritis 11/2020
1	Proteinuria 11/2020
1	Sepsis (Septicemia) 01/2020
1	Leukemia 01/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018
1	Injection Site Reaction 01/2017
1	Epistaxis (Nosebleed) 09/2014
1	Congenital Diaphragmatic Hernias 09/2013
1	Osteoporosis 01/2012
1	Protein C Deficiency 04/2010
1	Protein S Deficiency (Deficiency, Protein S) 04/2010

Drug/Important Bio-Agent (IBA)

20	Factor VIII (Coagulation Factor VIII)IBA 06/2022 - 09/2012
20	emicizumabIBA 09/2021 - 01/2017
10	AnticoagulantsIBA 01/2022 - 09/2007
8	AntibodiesIBA 07/2022 - 10/2011
7	recombinant FVIIa (rFVIIa)FDA Link 07/2022 - 09/2007
7	Factor IX (Coagulation Factor IX)FDA LinkGeneric 11/2021 - 12/2014
7	Monoclonal AntibodiesIBA 09/2021 - 01/2019
6	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 03/2007
6	Prothrombin (Factor II)IBA 01/2021 - 01/2004
6	RivaroxabanIBA 10/2020 - 01/2018
5	Thrombin FDA Link 09/2021 - 01/2004
5	Blood Coagulation Factors (Coagulation Factor)IBA 01/2020 - 07/2011
5	Fondaparinux (Arixtra)FDA Link 01/2020 - 09/2007
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2016
4	nonacog beta pegolIBA 10/2020 - 12/2014
4	Neutralizing AntibodiesIBA 06/2019 - 01/2006
4	AntithrombinsIBA 10/2016 - 01/2004
3	Factor VII (Proconvertin)IBA 07/2022 - 09/2017
3	Pharmaceutical PreparationsIBA 01/2022 - 12/2011
3	Factor IXa (Coagulation Factor IXa)IBA 03/2021 - 01/2017
3	Factor VIIa (Activated Factor VII)IBA 01/2021 - 06/2008
3	bivalirudin (Angiomax)FDA Link 04/2011 - 09/2007
2	concizumabIBA 01/2022 - 11/2019
2	Hemostatics (Antihemorrhagics)IBA 03/2021 - 08/2009
2	SteroidsIBA 01/2021 - 01/2018
2	factor VIII-Fc fusion proteinIBA 05/2020 - 01/2016
2	Vitamin K FDA Link 01/2020 - 10/2019
2	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 10/2019 - 12/2008
2	Antiphospholipid AntibodiesIBA 10/2011 - 04/2010
2	ORALIT (ORS)IBA 10/2011 - 04/2010
2	argatroban (MPQA)FDA Link 01/2011 - 09/2007
2	Thromboplastin (Tissue Factor)IBA 06/2008 - 01/2004
1	BESIBA 07/2022
1	BAX 335IBA 11/2021
1	cyclo(Arg-Pro) (CI 4)IBA 01/2020
1	SuspensionsIBA 01/2020
1	TabletsIBA 01/2020
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 11/2019
1	Heme (Haem)IBA 01/2019
1	Factor VIIIaIBA 01/2017
1	Factor X (Stuart Factor)IBA 01/2017
1	Protein CIBA 10/2016
1	Protein SIBA 10/2016
1	IsoantibodiesIBA 05/2016
1	von Willebrand FactorIBA 05/2016
1	Antithrombin IIIIBA 09/2013
1	recombinant human thrombinIBA 04/2013
1	Rituximab (Mabthera)FDA Link 09/2012
1	factor V LeidenIBA 04/2010
1	Lipoprotein(a)IBA 04/2010

Therapy/Procedure

27	Therapeutics 05/2022 - 02/2005
11	Central Venous Catheters 01/2022 - 11/2013
8	Catheters 01/2022 - 05/2006
1	Length of Stay 01/2022
1	Perioperative Care 11/2021
1	Artificial Respiration (Mechanical Ventilation) 01/2021
1	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2019
1	Self Administration (Administration, Self) 09/2017
1	Tracheostomy 09/2014
1	Extracorporeal Membrane Oxygenation 09/2013
1	Endovascular Procedures 04/2011
1	Percutaneous Coronary Intervention 04/2011
1	Off-Label Use 08/2009